Lupus (SLE): who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 80
• BCMA 38
• STING 0
• CD20 9
• SGLT2 3
• STAT3 0
• NLRP3 0
• mTOR 0
• JAK 0
• TNF 0
• IL-17 1
• IL-6 0
• PI3K 0
• CD40 0
• TYK2 0
• CTLA-4 0
• FOXP3 0
• PD-1 0
• PPAR 0
• AMPK 0
• CD38 1
• IL-1 0
• NRF2 0
• TP53 0
• AKT 0
• AQP4 0
• CD22 1
• CXCR4 0
• IL-23 0
• APOL1 0
• BRD4 0
• BTK 0
• CTNNB1 0
• GPX4 0
• HIF-1 0
• HMGB1 0
• IL-15 1
• MAPK 0
• PD-L1 0
• SIRT1 0
• TIGIT 0
• TLR4 0
• ACE2 0
• ANGPTL3 0
• BCL-2 0
• CD123 0
• COX-2 0
• DPP-4 0
• ERK 0
• EZH2 0
• FGFR 0
• FTO 0
• G6PD 0
• GLP-1 0
• IDO1 0
• IL-4 0
• KRAS 0
• LAG-3 0
• MDM2 0
• METTL3 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F30

  Identification and functional characterization of ultra-rare variants in childhood lupus

  University of Oklahoma Hlth Sciences Ctr· Oklahoma City, United States· US$38,889 awarded in fiscal year 2026· until Oct 2029

• NIH NIAID · F30

  Regulation of type I interferon signaling by A20 (TNFAIP3) in autoimmune and autoinflammatory disease

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$55,114 awarded in fiscal year 2026· until Oct 2029

• NIH NIAID · F31

  Genetic and cellular mechanisms underlying resistance to gammaherpesvirus infection

  University of Vermont & St Agric College· Burlington, United States· US$34,654 awarded in fiscal year 2026· until Sept 2028

• NIH NIDCR · R01

  Restoring responses to immunotherapy in metastatic lymph nodes in HNSCC

  University of California, San Francisco· San Francisco, United States· US$684,832 awarded in fiscal year 2026· until Jul 2031

• NIH NIA · R41

  Brain-targeted antibody for Alzheimer's disease therapy

  Nanopx Biosciences, Llc· Chapin, United States· US$483,457 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Metabolic microenvironments in humoral immunity (MicroMeta)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €1,990,728· until Jan 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Early and sensitive detection of renal involvement and treatment responses in lupus patients using non-invasive biomarkers (EARLINESS)

  Fundacion Publica Andaluza Progreso y Salud M.p.· Sevilla, Spain· EU contribution €226,441· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Understanding the Interaction of T cells and Immune Complexes in Systemic Lupus Erythematosus (TICI-SLE)

  Charite - Universitaetsmedizin Berlin· Berlin, Germany· EU contribution €265,648· until Aug 2027· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  SInGle cells iN AuToimmUne inflammatoRy disEases (SIGNATURE)

  Fundacion Publica Andaluza Progreso y Salud M.p.· Sevilla, Spain· EU contribution €2,630,239· until Dec 2026· 7 countries

9 of 887 running projects, newest first. Listed amounts together: US$550.9m + €5.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 33
• Mendelian Randomization Analysis 42
• CRISPR-Cas Systems 1
• Gene Expression Profiling 102
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 35
• Metabolomics 23
• Mass Spectrometry 5
• Flow Cytometry 35
• Immunohistochemistry 8
• Liquid Biopsy 2
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 49
• Machine Learning 38
• Deep Learning 3
• Cohort Studies 112
• Genome-Wide Association Study 55

• An Exploratory Clinicopathological Study Investigating Immunohistochemical Markers (CD61 and Fibrin) for Detecting Platelet Aggregates and Fibrin Deposition in Lupus Nephritis.

  Int J Rheum Dis, Sept 2026

• Kidney-infiltrating proteinase 3-positive granulocytes are abundant in lupus nephritis.

  Rheumatology (Oxford), Sept 2026

• Interstitial palladin is associated with tubulointerstitial chronicity and adverse outcomes in patients with lupus nephritis.

  Lupus, Aug 2026

• A case of lupus nephritis combined with fibrillary glomerulonephritis diagnosed using mass spectrometry and immunohistochemistry of DNAJB9.

  Clin Nephrol, Jul 2026

• Differential glomerular expression patterns of Th17-related cytokines in Mexican patients with lupus nephritis.

  Lupus, Nov 2025

• Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3.

  J Immunol, Feb 2017

• Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis.

  Curr Med Chem, Jan 2012

• Treatment of indeterminate cell histiocytosis with pravastatin.

  J Am Acad Dermatol, May 2011

See which targets of this disease your abstract mentions, and go to the people working on them.